ClinicalTrials.gg
CompletedNCT07147010EvoUpdated Dec 9, 2025

Evaluation of Correlations Between Volatile Organic Compounds and Venous Blood Glucose in Subjects With Type 2 Diabetes

An interventional study of MIB Breath Analyzer in Type 2 Diabetes, sponsored by DCB Research AG. Completed at 1 site in Switzerland. Open to participants aged 45 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by DCB Research AG · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Oct 2024, registered Aug 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
45 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 112 studies in Diabetes Mellitus, Type 2 with a site in Switzerland — 13 open to participants now, 18 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Switzerland.

Enrollment
88th of 91
20 · median 330
Started
2024
with 2 others
No phase
22 of 112
6 open now
Registered
107th of 112
by date

Among the 112 studies in Diabetes Mellitus, Type 2 with a site in Switzerland, this one is the 88th largest by enrollment of the 91 interventional ones that give a count, is one of 3 that started in 2024, is one of 22 with no phase, and was the 107th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

13 of the 112 studies in Diabetes Mellitus, Type 2 with a site in Switzerland are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 45 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Diabetes Mellitus, Type 2 with a site in Switzerland, or all of them as a file.
02

Study summary

The goal of this study is to evaluate correlations between VOCs in the breath and venous blood glucose values in various glycaemic states in people living with Type 2 Diabetes.

VOCs are measured with a gold-standard GC-IMS device and a prototype of a novel breath analyzer. Participants will be exposed to different blood glucose levels at different rates of change by administering glucose solution and insulin and by a meal challenge.

Read the detailed description

The research project aims to expand the understanding of correlations between VOCs in the breath and venous blood glucose levels in non-insulin-dependent people with Type 2 Diabetes. To better understand correlations, the subjects are exposed to hyperglycaemic, euglycaemic and hyposglcycaemic states at different rates of change by applying a hand clamp procedure, and the VOCs are compared after a standardized meal and the same excursion by applying a hand clamp procedure. Inter- and intraparticipant variability as well as the timing of changes in the VOC spectra compared to changes in the glucose values are of interest. Secondarily, the feasibility of estimating glycaemic states with a prototype of a novel breath analyzer is being investigated.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • Volatile Organic Compounds
  • Glucose excursions
  • Rates of change of glucose values
  • Hyperglycaemia
  • Hypoglycaemia
  • Gas Chromatography - Ion Mobility Spectrometry
  • Euglycaemia
  • Breath-analysis
04

Who can participate

Ages eligible
45 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written
  • T2D treated with one or more oral anti-diabetic drugs (incl GLP-1 and/or GIP)
  • \< 10 years since T2D diagnosis
  • ≤8% (HbA1c based on last measurement by treating physician but not older than 120 days)
  • Willingness to undergo study procedures
  • Age 45 -70 years (inclusive)

Exclusion criteria

Exclusion Criteria:

  • Pregnancy and/or lactation period
  • Currently on chronic or occasional treatment with pulmonary drugs
  • Insulin dependency
  • Smoking (last cigarette within the last six months)
  • above 30 kg/m²
  • Lp(a) above 125 nmol/l
  • LDL not in the individual target range of an earlier cholesterol goal according ESC guideline 2021 (LDL based on last measurement by treating physician but not older than 30 days)
  • Irregular 12-lead or increased carotid plaque burden based on a three-point sonography. Both examinations are performed and evaluated according to the investigator's judgment.
  • History of, or manifested, cardiovascular diseases
  • Medical history of epilepsy or other neurological disease associated with seizure events
  • Known sensitivity to medical grade adhesives
  • Comorbidities that are suspected to alter the VOC spectra
  • Participation in another investigation with an drug within the 30 days preceding and during the present investigation
  • Not able to understand, write or read German
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    People with Type 2 Diabetes

    Exposure to various glycaemic states at different rates of change by administering glucose solution, insulin, or a standardized meal.

    Device: MIB Breath Analyzer

Interventions

  • DeviceMIB Breath Analyzer

    Going through visit-specific blood glucose excursions by the administration of glucose and insulin (clamp), monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC-IMS and the MIBs (investigational devices). Going through visit-specific blood glucose excursions by consuming a standardized meal, monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC-IMS and the MIBs (investigational devices) Imitating the glucose excursion from the meal excursion by infusing glucose and insulin (clamp), monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC-IMS and the MIBs (investigational devices).

    Also known as: GC-IMS as gold standard

06

What researchers measure

Primary outcomes

  1. VOC spectra

    Primary outcome focuses on VOC spectra (measured with the GC-IMS) across varying intravenous blood glucose levels

    Time frame: 6-8 hour study visit

Secondary outcomes

  1. Inter-Participant VOC Variability

    Evaluation of VOC spectral differences measured with the GC-IMS among participants under identical glycemic states.

    Time frame: 6-8 hour study visit

  2. Intra-Participant VOC Variability

    Comparison of VOC spectral differences measured with the GC-IMS within the same participant across different glycemic states.

    Time frame: 6-8 hour study visit

  3. MIB VOC Spectra Analysis

    Investigation of VOC spectra (measured with the MIB) in diverse intravenously measured glycemic states.

    Time frame: 6-8 hour study visit

  4. VOC Spectra Response Time

    Assessment of the delay in VOC spectral shifts relative to changes in venous glucose from fluctuating to stable states at different change rates.

    Time frame: 6-8 hour study visit

  5. Comparison of meal vs clamp induced VOC changes

    Analysis of VOC spectral differences between natural post-meal glucose increases and clamp-induced glucose elevations measured with the GC-IMS.

    Time frame: 6-8 hour study visit

07

Study locations

1 site
  • Inselspital Bern
    Bern, 3010, Switzerland
08

References and documents

Individual participant data

Plan to share: No — There is no plan to share data regarding the main aims of the study.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Mar 2025, 5 months.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 5 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2025
First posted
Aug 28, 2025
StartActual
Oct 1, 2024
Primary completionActual
Mar 30, 2025
CompletionActual
Nov 27, 2025
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07147010
Lead sponsor
DCB Research AG
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
Oct 1, 2024
Primary completion
Mar 30, 2025
Completion
Nov 27, 2025
Last update
Dec 9, 2025

Study contacts

Frank Flacke, Dr.
study chair · BOYDSense SAS
Markus Laimer, Dr. med
principal investigator · Inselspital Bern, Switzerland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion